trending Market Intelligence /marketintelligence/en/news-insights/trending/aOWg8UXsD_yRzLfTEiRyYQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Immune Therapeutics plans to acquire private Aletheia in all-stock deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Immune Therapeutics plans to acquire private Aletheia in all-stock deal

Immune Therapeutics Inc. said it will acquire privately held Aletheia Therapeutics Corp., which develops cancer therapies, in an all-stock deal.

Orlando, Fla.-based Immune Therapeutics expects to complete the transaction in the first quarter of 2020, subject to completion of a definitive agreement, the employment of the Aletheia management team to Immune management team and the assignment of all intellectual property to Immune.

Selected directors of Aletheia will join the board of the combined company as part of the acquisition, Immune Therapeutics noted in its Dec. 16 press release.

Additionally, Aletheia has agreed to sell an investor group securities for $25 million that will be funded before the end of the year.

Financial details of the transaction were not disclosed.

Immune Therapeutics develops immunotherapies for autoimmune and inflammatory diseases, cancer, HIV/AIDS and animal diseases.